






















Stage 2 T1D Disease Modifying Therapy Clinical Trials (Multi-site)		
 DRUG	<p>A Study of Baricitinib for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY) AGES 1-36 STAGE 2 T1D (AT LEAST 2 AUTOANTIBODIES) ORAL PILL</p>	
Stage 2 T1D Disease Modifying Therapy Clinical Trials (Single site)		
 DRUG	<p>GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab (GLP-TEP) AGES 12-50 STAGE 2 T1D (AT LEAST 2 AUTOANTIBODIES) ORAL PILL VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN</p>	
Stage 3 T1D Disease Modifying Therapy Clinical Trials (Multi-site)		
 DRUG	<p>A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) AGES 1-36 WITHIN 8 WEEKS OF DIAGNOSIS ORAL PILL</p>	

 DRUG	<p align="center"> A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes (BETA PRESERVE) AGES 1-25 WITHIN 8 WEEKS OF DIAGNOSIS IV INFUSION </p>	
 DRUG	<p align="center"> Targeting Type 1 Diabetes Using POLyamines (TADPOL) AGES 4-40 WITHIN 100 DAYS OF DIAGNOSIS ORAL PILL </p>	
 DRUG	<p align="center"> Precision Administration of Anti-thymocyte Globulin With or Without Verapamil AGES 6-36 WITHIN 100 DAYS OF DIAGNOSIS IV INFUSIONS AND ORAL PILL </p>	
 DRUG	<p align="center"> Rezpegaldesleukin in New Onset Type 1 Diabetes Mellitus AGES 8-45 WITHIN 100 DAYS OF DIAGNOSIS INJECTIONS </p>	

 DRUG	<p>A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (WAVE T1D) AGES 9-21 WITHIN 6 MONTHS OF DIAGNOSIS IV INFUSION</p>	
 DRUG	<p>CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) AGES 12-35 DIAGNOSED FOR LESS THAN 6 MONTHS IV INFUSIONS</p>	
 DRUG	<p>FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adults and Adolescents on Top of inSulin Therapy (FABULINUS) AGES 12-35 WITHIN 3 MONTHS OF DIAGNOSIS INFUSION FOLLOWED BY INJECTIONS</p>	
 DRUG	<p>SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes (SAFEGUARD) PART A AGES 15-40 PART B AGES 5-40 WITHIN 100 DAYS OF DIAGNOSIS IV INFUSION</p>	

 DRUG	<p align="center">Denosumab for Type 1 Diabetes FEMALES AGES 18-50 MALES AGES 21-50 DIAGNOSED FOR ≥ 12 months but ≤ 5 years INJECTION</p>	
 DRUG	<p align="center">A Study of GNTI-122 in Adults Recently Diagnosed With T1D (POLARIS) AGES 18-55 WITHIN 120 DAYS OF DIAGNOSIS SINGLE IV INJECTION</p>	
<p>Stage 3 Disease Modifying Therapy Clinical Trials (Single site)</p>		
 DRUG	<p align="center">PREBIOTICS IN PATIENTS WITH TYPE 1 DIABETES AGES 7+ (Lead Site) AGES 7-17 (Subsites) DIAGNOSED FOR LESS THAN 12 MONTHS ORAL PILL UNIVERSITY OF CALGARY</p>	

 DRUG	<p>Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells AGES 18-40 DIAGNOSED FOR LESS THAN 6 MONTHS INFUSION MEDICAL UNIVERSITY OF SOUTH CAROLINA</p>	
 DRUG	<p>An Adaptive Design of MTX228 AGES 18-65 DIAGNOSED FOR AT LEAST 1 YEAR ORAL PILL UNIVERSITY OF ALBERTA</p>	
<p>Trial Tools & Contact Information</p>		
 TRIAL TOOLS	<p>Clinical Trials Connection Tool Match to a clinical trial in 60 seconds</p>	
 CONTACT INFO	<p>Clinical Trial Education Volunteers Your key to participation! Connect with a local volunteer trained to answer any questions you may have.</p>	